Liquid embolism material and preparation method thereof

Through the combination adjustment of thixotropic agent and developer, a liquid embolization material was prepared, which solved the safety risks brought by gelatin and the limited sterilization method, achieved performance matching under different shear states, and ensured the safety and delivery stability of the embolization material.

CN120550175APending Publication Date: 2025-08-29DIGRAY MEDICAL TECH (SUZHOU) CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202510722621.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-05-30
Publication Date
2025-08-29

AI Technical Summary

Technical Problem

The gelatin components in existing liquid embolization materials have risks of viral transmission and immunogenicity, and the sterilization method is limited, making it difficult to meet viscosity and modulus requirements under different shear conditions, affecting product performance and safety.

Method used

Use a combination of thixotropic agent and developer to adjust their proportions to prepare a liquid embolization material, use irradiation sterilization method, omit gelatin to ensure safety and performance meet the requirements.

Benefits of technology

It realizes embolization performance with low viscosity and stable modulus in low shear state, avoids safety risks brought by gelatin and crack problems caused by wet and heat sterilization, and meets the performance requirements of embolization materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005429780570000041
    Figure BDA0005429780570000041
  • Figure BDA0005429780570000051
    Figure BDA0005429780570000051
  • Figure BDA0005429780570000071
    Figure BDA0005429780570000071
Patent Text Reader

Abstract

According to the liquid embolism material and the preparation method thereof disclosed by the invention, a traditional thickening agent is omitted, and the prepared liquid embolism material has better flowability in a high-shear state by adjusting the specific types and dosage proportions of a developing agent and a thixotropic agent, and is convenient to convey to a farther end of a blood vessel; and meanwhile, under a low-shear state, high shear viscosity and modulus are presented, the performance requirement of embolism stability is met, and the immunogenicity risk and the limitation of a sterilization mode caused by a traditional thickener gelatin can be avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to a liquid embolic material and a preparation method thereof. Background Art

[0002] Embolic materials can be used to stop and prevent bleeding, halting the blood supply to abnormal tissues such as malignant or benign tumors and hyperplastic organs. Embolic agents used in clinical practice can be divided into two types: solid embolic materials and liquid embolic materials. Gelatin, due to its easy availability and good tissue compatibility, is degraded and absorbed within 14-90 days in the body. Historically, it was the most widely used vascular embolic agent in interventional therapy and is currently also commonly used as a raw material for liquid embolic agents. In shear-thinning liquid embolic agents, gelatin acts as a thickener and, when uniformly mixed with a thixotropic agent in varying proportions, creates highly thixotropic liquid embolic agents with varying viscosities and solidification properties. The gel embolic material described in patent CN117442772A exhibits shear-thinning properties. Under injection pressure, it transforms into a pseudoplastic fluid, facilitating delivery. Upon removal of the force, it returns to its original semisolid gel state, achieving embolic occlusion. However, the hydrogel described in this patent has many components and a complex process. Moreover, one of the components, medical gelatin, is obtained by partial hydrolysis of collagen contained in animal skin, bones, and joints, which will increase safety risks in terms of virus transmission and immunogenicity.

[0003] Common sterilization methods include irradiation and moist heat sterilization. Because irradiation sterilization generates free radicals in water, which attack gelatin molecules, crosslinking them and generating water and hydrogen, forming a water-insoluble gel and bubbles, which can affect the performance of the embolic agent. Therefore, gelatin-containing liquid embolic agents cannot be sterilized using conventional irradiation. Furthermore, moist heat sterilization can cause cracks in the hydrogel, affecting its appearance.

[0004] To overcome the safety risks and limited sterilization methods of gelatin-containing liquid embolic agents, one approach is to omit gelatin and use a thixotropic agent alone. However, since embolic agents require low shear viscosity under high shear conditions to facilitate delivery through a catheter, and high shear viscosity and modulus under low shear conditions to ensure stable embolization, omitting gelatin makes it difficult to simultaneously increase the modulus under low shear conditions without significantly increasing the viscosity under high shear conditions. This patent achieves low viscosity under high shear conditions and high modulus under low shear conditions by adjusting the ratio of the developer and thixotropic agent. Summary of the Invention

[0005] The present invention provides a liquid embolic material and a preparation method thereof. The material composition is safe and has no risks such as viral transmission and immunogenicity. It can also meet the viscosity and modulus requirements under different shear states, making it more conducive to catheter delivery while maintaining the embolic strength. At the same time, it can be sterilized by irradiation to prevent cracks in the hydrogel and affect the product appearance.

[0006] In order to achieve the above technical objectives, in a first aspect, the present invention discloses a liquid embolic material, which is composed of a thixotropic agent, sterile water for injection, and a developer.

[0007] Furthermore, the weight of the developer accounts for 20wt%-35wt% of the total weight of the thixotropic agent, sterile water for injection and the developer, and the weight of the thixotropic agent accounts for 8wt%-16wt% of the weight of the developer.

[0008] Furthermore, the weight of the developer accounts for 27.5wt%-30.7wt% of the total weight of the thixotropic agent, sterile water for injection and the developer, and the weight of the thixotropic agent accounts for 9.4wt%-11wt% of the weight of the developer.

[0009] Furthermore, the thixotropic agent is silicate.

[0010] Furthermore, the thixotropic agent is nano-lithium magnesium silicate.

[0011] Furthermore, the developer is tantalum powder.

[0012] In a second aspect, the present invention further discloses a method for preparing the liquid embolic material as described above, comprising the following steps:

[0013] S1. Weigh the raw materials according to the weight ratio, add the developer and thixotropic agent to sterile water for injection, and vacuum disperse to obtain a hydrogel embolic agent;

[0014] S2, vacuum filling the hydrogel embolic agent into the syringe;

[0015] S3. Irradiation sterilization.

[0016] Furthermore, in S1, a vacuum stirring degassing machine is used to perform vacuum dispersion to obtain a hydrogel embolic agent.

[0017] Furthermore, the rotation speed of the vacuum stirring degassing machine in S1 is 200-2000 rpm, and the time is 1-30 min.

[0018] Furthermore, the temperature of the sterile water for injection in S1 is 0-10°C.

[0019] Beneficial effects of the present invention:

[0020] The embolic material of this application does not use traditional thickeners. By specifying the developer type and limiting the developer to thixotropic agent ratio, the resulting liquid embolic material meets the performance requirements of exhibiting low shear viscosity under high shear conditions, facilitating catheter delivery, and high shear viscosity and modulus under low shear conditions, promoting robust embolization. Only when the tantalum powder content accounts for 20wt%-35wt% of the total weight, and the thixotropic agent accounts for 8wt%-16wt% of the developer weight, can the embolic material maintain embolic strength under low shear conditions while also facilitating catheter delivery under high shear conditions.

[0021] The embolic material components of the present application are safe and do not present safety risks such as virus transmission and immunogenicity; radiation sterilization can be used to avoid hydrogel cracking caused by moist heat sterilization. DETAILED DESCRIPTION

[0022] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0023] Unless otherwise specified, the experimental methods in the following examples are conventional methods and were performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials and reagents used in the following examples, unless otherwise specified, were all commercially available.

[0024] Examples 1-4

[0025] Add 302.75 g of sterile water for injection cooled to 2°C, along with the nano-magnesium lithium silicate and tantalum powders (as listed in Table 1) to a mixing tank. Mix the mixture in a vacuum agitator at 1800 rpm for 5 minutes to produce a hydrogel embolic agent. The hydrogel embolic agent is then vacuum-filled into 1 ml syringes and sterilized by irradiation. The irradiation source used for sterilization is an electron accelerator with a power of 20 kW, an energy of 10 MeV, and an irradiation dose of 25 kGy.

[0026] Comparative Example 1: gelatin was used as a thickener and sterilized by moist heat sterilization.

[0027] Add 4.5g of gelatin and 25g of sterile water for injection to a flask. Stir at 70°C, 400 rpm, for 30 minutes to obtain a gelatin predissolve. Keep warm at 70°C until ready for use. Add 280.1g of sterile water for injection cooled to 2°C, 80g of tantalum powder, 13.21g of nano-lithium magnesium silicate, and 26.7g of the gelatin predissolve to a mixing tank. Stir at 1800 rpm in a vacuum stirring and degassing machine for 5 minutes to obtain a hydrogel embolic agent. Vacuum-fill the hydrogel embolic agent into 1ml syringes and sterilize with moist heat.

[0028] Comparative Example 2: gelatin was used as a thickener and the sterilization method was irradiation sterilization:

[0029] Add 4.5g of gelatin and 25g of sterile water for injection to a flask. Stir at 70°C, 400 rpm, for 30 minutes to obtain a gelatin predissolve. Keep warm at 70°C until ready for use. Add 280.1g of sterile water for injection cooled to 2°C, 80g of tantalum powder, 13.21g of nano-lithium magnesium silicate, and 26.7g of the gelatin predissolve to a mixing tank. Stir at 1800 rpm in a vacuum stirring and degassing machine for 5 minutes to obtain a hydrogel embolic agent. Vacuum-fill the hydrogel embolic agent into 1ml syringes and sterilize by irradiation.

[0030] Comparative Example 3, gelatin was omitted, the amount of tantalum powder used was less than that of Examples 1-4, and irradiation sterilization was performed:

[0031] 302.75 g of sterile water for injection cooled to 2°C, 13.21 g of nano-lithium magnesium silicate, and 80 g of tantalum powder were added to a stirring tank. The mixture was stirred at 1800 rpm in a vacuum stirring and degassing machine for 5 minutes to obtain a hydrogel embolic agent. The hydrogel embolic agent was vacuum-filled into a 1 ml syringe and sterilized by irradiation.

[0032] Comparative Example 4-7, omitting gelatin, using iohexol powder instead of tantalum powder, and irradiating for sterilization:

[0033] 302.75 g of sterile water for injection cooled to 2° C., nano-lithium magnesium silicate, and iohexol of the mass described in Table 1 were added to a stirring tank. The mixture was stirred at 1800 rpm in a vacuum stirring and degassing machine for 5 minutes to obtain a hydrogel embolic agent. The hydrogel embolic agent was vacuum-filled into a 1 ml syringe and sterilized by irradiation.

[0034] Table 1

[0035]

[0036]

[0037] Iohexol is a white powder that is highly soluble in water.

[0038] The following tests were performed on 11 hydrogel embolic agents prepared in Examples 1-4 and Comparative Examples 1-7:

[0039] 1. Appearance Test: Five testers conducted appearance tests on 11 hydrogel embolic agents provided in Examples 1-4 and Comparative Examples 1-7. The test criteria were whether there were visible cracks, bubbles, or lumps. The statistical test results are shown in Table 2:

[0040] Table 2

[0041] Sample name Are there cracks? Are there bubbles? Whether it is clumping Example 1 No cracks No bubbles No lumps Example 2 No cracks No bubbles No lumps Example 3 No cracks No bubbles No lumps Example 4 No cracks No bubbles No lumps Comparative Example 1 Cracks No bubbles No lumps Comparative Example 2 Cracks There are bubbles There are lumps Comparative Example 3 No cracks No bubbles No lumps Comparative Example 4 No cracks No bubbles No lumps Comparative Example 5 No cracks No bubbles No lumps Comparative Example 6 No cracks No bubbles No lumps Comparative Example 7 No cracks No bubbles No lumps

[0042] 2. Extrusion force test

[0043] Prepare a 130 cm long, 2.8 French diameter microcatheter. Fill the microcatheter with the liquid embolic material to be tested before testing. Connect the filled microcatheter to the syringe tip via a Luer connector. Secure the syringe with a clamp. Set the pushing speed to 30 mm / min and the test distance to 20 mm. Record the maximum and average pushing force of the syringe handle during the test to the nearest 0.1 N.

[0044] The test results are shown in Table 3:

[0045] Table 3

[0046] Sample name Maximum extrusion force / N Average extrusion force / N Example 1 26.37 19.83 Example 2 23.03 16.49 Example 3 24.64 17.75 Example 4 32.96 26.64 Comparative Example 1 30.95 23.08 Comparative Example 2 There are lumps and cannot be tested There are lumps and cannot be tested Comparative Example 3 18.43 11.29 Comparative Example 4 12.45 6.78 Comparative Example 5 11.24 6.01 Comparative Example 6 12.34 6.57 Comparative Example 7 13.05 6.98

[0047] 3. Modulus test

[0048] At 25°C, the strain was fixed at 1% and the frequency was 1 Hz, and a vibration time sweep was performed.

[0049] Test standard: ISO 6721-10-2025, instrument: HAAKE ViscotesteriQ rheometer with Peltier temperature control device, test the loss modulus and storage modulus of the sample after stabilization.

[0050] 4. Shear viscosity test

[0051] At 25℃, the rheometer was used to measure the shear rate from 0.001s -1 -1000s -1 The peristaltic scan was performed under the condition of shear rate of 0.01s -1 and 10s -1 The shear viscosity at , the unit is: millipascal second (mPa s).

[0052] The results of the modulus and shear viscosity tests are shown in Table 4:

[0053] Table 4

[0054]

[0055] Because irradiation sterilization of gelatin in aqueous solution induces crosslinking, the appearance test results for Comparative Example 2 showed cracks, bubbles, and lumps in the embolic material, affecting product performance. Comparative Example 1, sterilized by moist heat, exhibited cracks but no bubbles or lumps, which did not affect product performance but affected aesthetics. Comparative Examples 1-2 all exhibited cracks, while Examples 1-7 showed no cracks. This demonstrates that the liquid embolic materials prepared in Examples 1-4 of this application can be sterilized by irradiation, avoiding cracks caused by moist heat sterilization.

[0056] When doctors inject liquid embolic materials, if the required extrusion force is too high, the injection process will be hindered. The maximum extrusion force is required to be less than 40N. As shown in Table 4, in the formulations of Examples 1-4, the developer content ranged from 24% to 33.6% by weight, and the thixotropic agent content ranged from 8.3% to 13.2% by weight. The syringe rod extrusion forces of Examples 1-4 and Comparative Examples 1, 3-7 all met the required standards. While Examples 1-4 successively increased the proportion of tantalum powder, the extrusion forces of Examples 2 and 3 were lower than those of Examples 1 and 4. This indicates that when the developer content ranged from 27.5% to 30.7% by weight and the thixotropic agent content ranged from 9.4% to 11.0% by weight, the resulting liquid embolic material was more suitable for microcatheter delivery. These data and test results demonstrate that by adjusting the ratio of thickener to thixotropic agent, an embolic agent more suitable for microcatheter delivery can be obtained.

[0057] Comparative Examples 3 and 4, as well as Examples 2-4 and 5-7, all contained the same weight of different developer types. Comparative Examples 4-7 exhibited lower syringe handle extrusion force, shear viscosity, and modulus, demonstrating that different developer types can affect the viscosity and coagulation properties of liquid embolic agents. Because the shear viscosity of Comparative Examples 4-7 is too low, they lack a robust embolic effect and are washed away in the blood vessels, causing ectopic embolism. Therefore, they cannot be used as shear-thinning embolic agents. This demonstrates that not all developer types, when added in the same amounts as in Examples 2-4, can function as thickeners.

[0058] It can be seen from Table 4 that at low shear, i.e. 0.01s -1 At the shear rate, the shear viscosity of Examples 1-4 is between 2.9-3.4E+07, which is higher than the shear viscosity of Comparative Example 1 of 2.8E+07. The storage modulus and loss modulus of Examples 1-4 are both higher than Comparative Example 1, indicating that in the raw material system of Examples 1-4, tantalum powder can replace gelatin to play a thickening role and provide higher embolic strength in the blood vessel than Comparative Example 1. At high shear, that is, 10s -1At the shear rate, the shear viscosities of Examples 2 and 3 were 2.3E+07 and 2.5E+07, respectively, significantly lower than those of Examples 1 and 4, indicating a non-linear relationship between the amount of tantalum powder added and the mechanical properties of the resulting embolic material. The shear viscosity of Comparative Example 3 was higher than that of Comparative Example 1, while the storage modulus and loss modulus were significantly lower than those of Comparative Example 1. This demonstrates that when the amount of tantalum powder in the developer is less than 21%-35% by weight of the total weight, and the amount of thixotropic agent is greater than 8%-16% by weight of the developer, the embolic material exhibits poor transport properties under high shear conditions and low embolic strength under low shear conditions, failing to meet the performance requirements of liquid embolic materials.

[0059] The present invention omits traditional thickeners. By adjusting the specific types and dosage ratios of the developer and thixotropic agent, the prepared liquid embolic material has better fluidity under high shear conditions, facilitating delivery to more distal ends of blood vessels. At the same time, under low shear conditions, it exhibits high shear viscosity and modulus, which is beneficial to the performance requirements of stable embolism and meets the performance requirements of liquid embolic materials.

[0060] The embodiments of the present invention are described in detail above, but the contents described are only preferred embodiments of the present invention and should not be considered to limit the scope of the present invention. All equivalent changes and improvements made within the scope of the present invention should still fall within the scope of the patent coverage of the present invention.

Claims

1. A liquid embolic material, characterized in that: It consists of sterile water for injection, thixotropic agent and developer.

2. The liquid embolic material according to claim 1, characterized in that The weight of the developer accounts for 20wt%-35wt% of the total weight of the thixotropic agent, sterile water for injection and the developer, and the weight of the thixotropic agent accounts for 8wt%-16wt% of the developer.

3. The liquid embolic material according to claim 2, characterized in that The weight of the developer accounts for 27.5wt%-30.7wt% of the total weight of the thixotropic agent, the sterile water for injection and the developer, and the weight of the thixotropic agent accounts for 9.4wt%-11wt% of the developer.

4. The liquid embolic material according to claim 1 or 2, characterized in that The thixotropic agent is silicate.

5. The liquid embolic material according to claim 4, characterized in that The thixotropic agent is nano-lithium magnesium silicate.

6. The liquid embolic material according to claim 1 or 2, characterized in that The developer is tantalum powder.

7. A method for preparing a liquid embolic material, for preparing the liquid embolic material according to claims 1 to 6, characterized in that: The steps include: S1. Weigh the raw materials according to the weight ratio, add the developer and thixotropic agent to sterile water for injection, and vacuum disperse to obtain a hydrogel embolic agent; S2, vacuum filling the hydrogel embolic agent into the syringe; S3. Irradiation sterilization.

8. The method for preparing the liquid embolic material according to claim 7, characterized in that: In S1, a vacuum stirring degassing machine is used to perform vacuum dispersion to obtain a hydrogel embolic agent.

9. The method for preparing a liquid embolic material according to claim 7, characterized in that: The speed of the vacuum stirring degassing machine in S1 is 200-2000 rpm, and the time is 1-30 min.

10. The method for preparing a liquid embolic material according to claim 7, characterized in that: The temperature of the sterile water for injection in S1 is 0-10°C.

Citation Information

Patent Citations

  • Gel embolism material and preparation method thereof

    CN117442772A